Medicare CED Could Enable Expanded Use Of Expedited Drug Approvals, Policy Groups Suggest
Executive Summary
Based on stakeholder consultations, former FDA and CMS head Mark McClellan and former CMS official Sean Tunis present a potential upside for biopharma in broader use of Medicare coverage with evidence development. Pfizer executives participate in workshop on coordinating expedited drug approval, CED policies.
You may also be interested in...
Medicare Part B: Commentary By CMS Officials
CMS officials Jonathan Blum, Louis Jacques and Tamara Jensen addressed a number of Medicare Part B-related topics of interest to the biopharmaceutical industry at the FDA/CMS Summit, including reimbursement for high-priced oncology drugs, coverage with evidence development and national coverage determinations.
Medicare CED Could Enhance Efficiency Of FDA Post-Approval Studies – CMS Draft Guidance
Medicare’s coverage with evidence development policy could help enhance the efficiency of research conducted under FDA post-approval requirements, CMS says in a draft guidance on CED released Nov. 29.
Medicare CED Could Enhance Efficiency Of FDA Post-Approval Studies – CMS Draft Guidance
Medicare’s coverage with evidence development policy could help enhance the efficiency of research conducted under FDA post-approval requirements, CMS says in a draft guidance on CED released Nov. 29.